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Involvement of interleukin-8 in dialysis-related arthritis. To elucidate
the role of interleukin (IL)-8, a chemotactic factor for neutrophils, in
dialysis-related arthritis (DRA) of patients on long-term hemodialysis, the
concentration of IL-8 was measured in the synovial fluids of DRA patients
with acute arthralgia and joint swelling, and was compared with those in
patients with rheumatoid arthritis (RA) and patients with osteoarthritis
(OA). We noted a marked elevation of IL-8 in the joint fluids of patients
with DRA and RA as compared with OA. Furthermore, to determine the
role of IL-8 in synovitis, we examined the in vivo effect of intra-articular
injection of human recombinant IL-8 on leukocyte infiltration into the
joint space of rabbits. A single injection of IL-8 to the joints of rabbits
induced rapid infiltration of neutrophils into the joint space and synovial
tissues, which reached a maximum in four hours. The oral administration
of indometacin farnesil (a prodrug that is converted to indomethacin after
intestinal absorption) before the injection of IL-8 alleviated the infiltration
of neutrophils. When human synovial cells were incubated with tumor
necrosis factor (TNF)-a, the expression of IL-8 mRNA and IL-8 produc-
tion in the cultured synovial cells were increased. The TNF-a-stimulated
expression of IL-8 mRNA and IL-8 production in the cultured synovial
cells were markedly inhibited by dexamethasone. In conclusion, IL-8 levels
were markedly elevated in the joint fluids of patients with DRA. Inter-
leukin-8 released from synovial cells may be an important factor to induce
acute inflammation in DRA. Dexamethasone and indomethacin may be
effective for DRA by inhibiting the production and chemotactic actions of
IL-8, respectively.
The acute phase of inflammation is characterized by the
accumulation of leukocytes, particularly neutrophils, at the site of
tissue injury or infection. Neutrophils migrate according to the
concentration gradient of chemotactic factor(s) [1]. A polypeptide
leukocyte chemotactic cytokine, interleukin (IL)-8, consists of
72-amino acids with a molecular mass of 8 kDa in its mature form
[2]. Interleukin-8 exhibits in vitro chemotactic activity against
neutrophils [3], T lymphocytes [4] and basophils [5], affects the
adhesion of neutrophils to the endothelium [6] and induces the
trans-endothelial migration of neutrophils [7]. Interleukin-8 stim-
ulates the degranulation of neutrophils, leading to the release of
lysosomal enzymes and to the production of superoxide anion [2];
it is released from a variety of cells, including monocytes/macro-
phages, fibroblasts and endothelial cells in the presence of lipo-
polysaccharide (LPS), IL-1 and tumor necrosis factor (TNF)-a at
the sites of infection or tissue injury [2, 7–9]. Intradermal injection
of IL-8 causes infiltration of neutrophils as well as lymphocytes [4]
and its intra-articular administration induces destruction of syno-
vium in a neutrophil-dependent manner [10]. Furthermore, the
administration of neutralizing antibody against IL-8 inhibits neu-
trophil infiltration and tissue damage in several types of acute
infiltration [11, 12]. We demonstrated that hemodialysis (HD)
using regenerated cellulose dialyzers markedly increased plasma
IL-8 levels and IL-8 mRNA of peripheral blood mononuclear cells
in uremic patients [13], and that plasma IL-8 can be used as a
marker of biocompatibility of dialysis membranes [14]. These
results suggest that overproduction of IL-8 is essentially involved
in acute inflammatory lesions and occurs during HD in uremic
patients.
Inflammation of the synovial joints is a common feature of
rheumatoid arthritis (RA). During the course of disease, the local
production of a number of cytokines by proliferative synovial cells
as well as by infiltrating cells appears to account for various
pathological and clinical manifestations in RA [15]. These cyto-
kine factors can cause joint destruction either alone or in combi-
nation with other factors, and elevated levels of these mediators
were documented in the synovial fluids of patients with RA [15,
16]. Neutrophils also increase in number in some chronic inflam-
matory lesions such as inflamed joints with RA. Particularly
during acute inflammatory flares in RA, neutrophils have been
shown to increase in synovial fluid [17]. Increased amounts of IL-8
were detected in synovial fluids of patients with active RA [10].
Frequent complications of dialysis-related arthritis (DRA) are
recurrent or persistent arthralgia, restricted joint mobility and
recurrent articular swelling with joint effusion and synovitis [18,
19]. These symptoms most frequently occur in the joints of
shoulders and knees, followed by hips, wrists, elbows, acromiocla-
vicular joints and feet. In joint destruction with DRA, b2-
microglobulin (b2m) modified with advanced glycation end prod-
ucts (AGE) in amyloid deposits might induce monocyte
chemotaxis and secretion of IL-1, IL-6 and TNF-a by infiltrating
macrophages [20]. The local production of cytokines by prolifer-
ative synovial cells as well as by infiltrating cells may account for
many pathological and clinical manifestations in DRA. The
incidence of joint effusion reaches nearly 50% (5 of 11 cases) in
patients receiving dialysis for more than 10 years [21]. Recent
study using sonography also confirmed the high incidence (14 of
33 cases) of joint effusion in long-term HD patients [22]. Involve-
ment is frequently bilateral and accompanied by mild joint
discomfort. Occasionally, symptoms of acute pain are severe and
flank arthritis is noted upon physical examination. Interleukin-8
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may be involved in the occurrence of the acute inflammatory
lesions in DRA as observed in RA.
To elucidate the role of IL-8 in the acute inflammatory flares of
DRA, IL-8 levels in the joint fluids of the patients with arthralgia
and joint swelling were measured and the in vivo effect of IL-8 on
the infiltration of leukocytes into joint space and synovial tissue
was determined. Furthermore, the effects of indomethacin and
dexamethasone on the IL-8-induced infiltration of leukocytes and
TNF-a-stimulated expression of IL-8 mRNA and IL-8 production
in cultured synovial cells, respectively, were evaluated.
METHODS
Patients
Joint fluids were aspirated from knee, hip or shoulder joints of
six patients (5 males and 1 female) with DRA, when they
complained of acute arthralgia and swelling in the joints. The
patients were selected from a hemodialysis (HD) population of
411 patients. They ranged in age from 44 to 78 (mean 62.5) years,
and all received HD therapy using cuprammonium rayon mem-
branes for 4 hours three times a week. The duration of HD
therapy was 12.2 6 7.9 (mean 6 SD) years. All the patients
received a surgical operation for carpal tunnel syndrome associ-
ated with dialysis-related amyloidosis. Predonisolone (5 mg) was
injected into their affected joints followed by alleviation of their
symptoms. None of the patients with DRA had suffered from RA
or osteoarthritis (OA).
Joint fluids were also aspirated from the knee joints of nine
patients with RA (3 males and 6 females), and eight patients with
OA (4 males and 4 females).
Assay of IL-8, IL-1a, IL-1b and TNF-a in joint fluids
Concentration of IL-8 in joint fluid and culture medium was
measured by a two-step sandwich enzyme-linked immunosorbent
assay (human IL-8 ELISA kit; Toray-Fuji Bionics, Tokyo, Japan).
Concentrations of IL-1a, IL-1b and TNF-a in joint fluids were
measured by two-step sandwich enzyme-linked immunosorbent
assays (human IL-1a, IL-1b and TNF-a ELISA kits; Otsuka
Pharmacol Co., Tokyo, Japan). Concentration of b2m in joint
fluids was measured by radioimmunoassay using a b2-microglobu-
lin kit Eiken (Eiken-Kagaku, Tokyo, Japan).
Intra-articular injection of IL-8
Twenty adult male New Zealand white rabbits (body weight
2.5 ; 3.5 kg) were used (IL-8 group, 8 rabbits; IL-8 1 indometa-
cin farnesil group, 8 rabbits; saline group, 4 rabbits). Carrier-free
human recombinant IL-8 (0.5 mg; Bachem California, Torrance,
CA, USA) was diluted in 0.5 ml of sterile endotoxin-free saline
and injected into the joint space of the knee joint through the
suprapatellar ligament [IL-8 group, N 5 8 knee joints (4 rabbits)
for 4 hour experiment, N 5 8 knee joints (4 rabbits) for 8 hour
experiment]. Further, to determine the effect of indometacin
farnesil (Eisai, Tokyo, Japan) on the leukocyte accumulation in
the joint, indometacin farnesil was orally given at a dose of 90
mg/kg body weight just before the injection of IL-8 [IL-8 1
indometacin farnesil group, N 5 8 knee joints (4 rabbits) for 4
hour experiment; N 5 8 knee joints (4 rabbits) for 8 hour
experiment]. Indometacin farnesil is a prodrug, and is converted
after intestinal absorption to indomethacin by carboxyesterase in
the liver, the kidneys and inflammatory lesions. An equal amount
of saline (0.5 ml) was also injected into the contralateral knee
joint as a control [saline group, N 5 4 knee joints (2 rabbits) for
a 4-hour experiment; N 5 4 knee joints (2 rabbits) for an 8-hour
experiment]. The animals were killed four or eight hours after
injection of IL-8 or saline by the administration of Nembutal. One
milliliter of sterile Hanks balanced salt solution (HBSS) was
injected into the joint cavity. After manipulating the joint gently to
mix the contents of the synovial cavity, the joint fluids from the
saline and IL-8-treated joints were carefully collected and centri-
fuged for three minutes at 3000 g in a microcentrifuge. The
infiltrated cells were resuspended in HBSS. The total cell number
of leukocytes, after being stained with Turk solution, were deter-
mined using a hemocytometer. This was followed by Wright-
Giemsa solution staining for differential leukocyte count. These
cells were also examined for a-naphthyl butylate esterase staining
and the rosette formation with 2-aminoethylisothiouronium bro-
mide (AET)-treated sheep erythrocytes (SRBC).
Light microscopic analysis
At specified intervals following a single injection of recombi-
nant IL-8 or saline, synovial tissue was dissected for histopatho-
logical examination at different sites of injection. Tissue samples
were fixed in neutral buffered formalin and embedded in paraffin
wax. Thin sections (3 ; 4 mm) were stained with hematoxylin and
eosin and examined by light microscopy.
Isolation of synovial cells and its cultures
Synovial tissues were obtained from knee joints by arthroscopic
biopsy performed on patients with traumatic injury. Synovial cells
were isolated from the explant by collagenase digestion and
cultured in a plastic culture flask (Falcon Plastic Inc., Los Angeles,
CA, USA) in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 50 U/ml penicillin G, 50 mg/ml streptomycin
(GIBCO BRL/Life Technologies, Inc., Grand Island, NY, USA),
1 mg/ml amphotericin B (ICN Biomedicals Inc., Costa Mesa, CA,
USA) and 10% fetal bovine serum (Cell Culture Lab., Cleveland,
OH, USA). The cells between the 4th and 10th passages were
used for the experiments.
Treatment of the synovial cells
When synovial cells were grown to confluency, the medium was
replaced with DMEM containing 1 mg/ml of bovine serum
albumin (BSA; Itohan Foods Inc., Hyogo, Japan) (BSA-DMEM)
and incubated for 25 to 28 hours. The experiment was initiated by
replacing the medium with BSA-DMEM with or without 1026 ; 28
M dexamethasone. After incubation for one hour, TNF-a (0.5 ng/ml)
was added and the cells were incubated another six hours for
Northern blot analysis or 24 hours for ELISA.
Human recombinant TNF-a (2.5 3 104 U/mg) was obtained
from Asahi Chemical Industry Co. Ltd. (Tokyo, Japan) and
diluted with DMEM (GIBCO BRL/Life Technologies, Inc.,
Grand Island, NY, USA) immediately before use.
Northern blot analysis
cDNA for IL-8 and human glyceraldehyde-3-phosphate-dehy-
drogenase (GAPDH) were prepared by polymerase chain reac-
tion (PCR) using the product of reverse transcription of mRNA
from TNF-a stimulated synovial cells. Oligonucleotide primers to
Takayama et al: IL-8 in dialysis-related arthritis1008
amplify the respective cDNA were as follows: IL-8, 59-ATTCT-
CAGCCCTCTTCAAAA-39 and 59-TCTGCAGCTCTGTGT-
GAAGG-39; GAPDH, 59-TTCATTGACCTCAACTACAT-39
and 59-GAGGGGCCATCCACAGTCTT-39. The expected sizes
of the cDNA were 240 and 465 base pairs for IL-8 and GAPDH,
respectively. After PCR amplification each fragment was cloned
into pCR1000 plasmid (TA cloning system; Invitrogen, San Diego,
CA, USA) according to the supplier’s protocol. The cloned cDNA
was used as probes for Northern blot analysis.
Total RNA was extracted from synovial cells by the method of
Chomcynski and Sacchi [23]. Total RNA (4 ; 10 mg) was
denatured in 10 mM phosphate buffer (pH 7.0), 50% dimethyl
sulfoxide and 1 M glyoxal, and was separated by electrophoresis on
0.8% agarose gels. The RNA was transferred onto a nylon filter
(Gene Screen Plus; New England Nuclear, Boston, MA, USA).
The membrane was prehybridized in buffer containing 50%
formamide, 900 mM NaCl, 5 mM EDTA, 50 mM sodium phosphate
(pH 7.4), 1% sodium dodecyl sulfate (SDS), 5 3 Denhardt’s
solution [0.1% Ficoll (molecular weight 400,000), 0.1% polyvi-
nylpyrrolidone (molecular weight 360,000), 0.1% BSA], and de-
natured herring sperm DNA (0.1 mg/ml) for at least four hours at
42°C. Heat denatured cDNA probes were labeled with [32P]dCTP
(111 TBq/mmol; New England Nuclear) using the Random
Primed DNA Labeling Kit (Boehringer Mannheim, Mannheim,
Germany). Labeled cDNA probes were added to the solution and
the hybridization was continued for 20 hours at 42°C. After
hybridization, the membranes were washed in 2 3 SSC (300 mM
NaCl, 30 mM sodium citrate) at 20°C (2 3 5 min), 2 3 SSC and
1% SDS at 65°C (2 3 30 min), and 0.1 3 SSC (15 mM NaCl, 1.5
mM sodium citrate) at 20°C (2 3 10 min) and exposed to Kodak
X-AR film (Eastman Kodak Co., Rochester, NY, USA) for
autoradiography. The amount of RNA was determined by scan-
ning densitometry (Image Analyzer, Immunomedica Co. Ltd.,
Shizuoka, Japan) of the band and expressed in arbitrary units.
STATISTICS
The results are expressed as mean 6 SE with a significance of
P , 0.05. For comparison of multiple groups ANOVA was
performed and Fisher’s PSLD was used.
RESULTS
Levels of IL-8 and the other cytokines in the synovial fluids
from affected joints of patients with DRA
As shown in Figure 1, the IL-8 levels were markedly increased
in the joint fluids of patients with DRA (7920 6 4330 pg/ml, P ,
0.05) as well as RA (12700 6 2700 pg/ml, P , 0.01), compared
with OA (284 6 211 pg/ml). The concentrations of IL-1a in the
joint fluids of all the patients with DRA, RA and OA were below
the detection limit (less than 7.8 pg/ml) and the concentrations of
IL-1b in the joint fluids of all the patients with DRA, RA and OA,
except one case with DRA (73.4 pg/ml) and one with RA (22.8
pg/ml), were below the detection limit (less than 15.6 pg/ml).
Tumor necrosis factor-a in the joint fluid was detected in three
patients with DRA (mean 22.9 pg/ml ranging from 17.6 to 27.7
pg/ml) and two patients with RA (95.3 and 35.9 pg/ml), but could
not be detected in the other patients with DRA and RA nor all
the patients with OA (less than 7 pg/ml). The levels of IL-8 were
significantly higher in the synovial fluids of the three DRA
patients (15100 6 6500 pg/ml, P , 0.05) with detectable levels of
TNF-a in their synovial fluids than the other DRA patients
(727 6 87 pg/ml) without detectable levels of TNF-a. The levels
of b2m in the synovial fluids were significantly increased in the
DRA patients (17.1 6 4.8 mg/ml, P , 0.05) as compared with
those in OA (3.1 6 1.0 mg/ml) and RA (2.7 6 0.5 mg/ml).
However, the b2m levels in the synovial fluids of DRA patients did
not show any significant correlation with their levels of IL-8 or
TNF-a.
Effect of indometacin farnesil on IL-8-induced infiltration of
leukocytes into the synovial cavity and synovial tissue
Figure 2 shows the effect of IL-8 injection on leukocyte
accumulation in the joint space and its time course. Saline caused
a small number of leukocytes to accumulate four hours after
injection. An intra-articular injection of IL-8 (0.5 mg) rapidly
induced infiltration of leukocytes into the joint space with maxi-
mal accumulation four hours after injection. The oral administra-
tion of indometacin farnesil just before the injection of IL-8
reduced leukocyte infiltration into the joint space. Accumulation
of neutrophils and mononuclear cells were present in the joint
wash fluids of the IL-8-induced synovitis. Neutrophils consisted of
89% of the infiltrated leukocytes. By light microscopic examina-
tion, most of these mononuclear cells were small, round and
positive for a-naphthyl butylate esterase staining. About 80% of
the infiltrated mononuclear cells were positive for rosette forma-
tion with AET-treated SRBC, indicating that these small mono-
nuclear cells were T lymphocytes, which were 9% of the infiltrated
leukocytes.
As shown in Figure 3A, a large number of leukocytes had
infiltrated into the superficial layers of the synovium four hours
after the injection of IL-8 comparing with the synovium four hours
after injection of saline (Fig. 3C). The oral administration of
indometacin farnesil just before the injection of IL-8 reduced
leukocyte infiltration into the synovial tissue (Fig. 3B).
Fig. 1. Concentrations of interleukin (IL)-8 in joint fluids of patients
with dialysis-related arthritis (DRA), rheumatoid arthritis (RA) and
osteoarthritis (OA). IL-8 levels in DRA and RA were markedly increased
compared with OA. Data are expressed as mean 6 SE (N 5 8 for OA, N 5
6 for DRA and N 5 9 for RA). *P , 0.05 and **P , 0.01 vs. OA.
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Effect of dexamethasone on TNF-a-stimulated expression of
IL-8 mRNA
When synovial cells were incubated with TNF-a for six hours,
the level of IL-8 mRNA was markedly increased (Fig. 4). To
examine whether dexamethasone suppresses TNF-a-stimulated
expression of IL-8 mRNA, the synovial cells were incubated with
1026 ; 28 M dexamethasone for one hour before the addition of
TNF-a. The incubation with dexamethasone and TNF-a was
continued for six hours. As shown in Figure 4, the dexamethasone
reduced TNF-a-stimulated expression of IL-8 mRNA in a con-
centration dependent manner, reaching a plateau at 1027 M. The
dose of dexamethasone (1027 M) reduced IL-8 mRNA to about
40% of the level stimulated by TNF-a.
Effect of dexamethasone on TNF-a-stimulated production of
IL-8
To examine whether dexamethasone suppresses TNF-a-stimu-
lated production of IL-8, the synovial cells were incubated with
1027 M dexamethasone for one hour before the addition of
TNF-a. The incubation of the cells with dexamethasone and
TNF-a was continued for 24 hours. As shown in Figure 5, the
addition of TNF-a resulted in a marked increase in IL-8 (7720 6
740 pg/ml, N 5 4) compared with controls (14.9 6 0.8 pg/ml, N 5
4). Dexamethasone reduced the TNF-a-stimulated IL-8 synthesis
to about 50% (4000 6 180 pg/ml, N 5 4).
DISCUSSION
In this study we have shown that IL-8 levels were increased in
the synovial fluids of patients with DRA. We demonstrated that
intra-articular injection of IL-8 increased leukocyte infiltration
into joint space and the oral administration of indometacin
farnesil reduced leukocyte infiltration in IL-8-induced acute sy-
novitis. Further, TNF-a stimulated the expression of IL-8 mRNA
and IL-8 production in cultured synovial cells, and the TNF-a-
stimulated expression of IL-8 mRNA and IL-8 production were
inhibited by dexamethasone. Although TNF-a was detectable in
the synovial fluids in three of the six patients with DRA, the levels
of IL-8 in the synovial fluids were significantly higher in the three
DRA patients with detectable levels of TNF-a in their synovial
fluids than the other DRA patients. Thus, elevation of IL-8 is not
unique in the setting of inflammatory arthritis, and the elevation
of IL-8 in the synovial fluids of patients with DRA may be partly
due to TNF-a-induced IL-8 production by synovial cells. Inter-
leukin-8 may be involved in acute inflammatory flares of DRA,
since IL-8 induces neutrophil infiltration and neutrophil-mediated
cartilage breakdown as a result of induction of neutrophil degran-
ulation by the cytokine [24].
The intra-articular injection of IL-8 induced rapid infiltration of
leukocytes into the synovium and joint cavity, with a maximal
response occurring four hours after the injection. At that time
neutrophils were present in the greatest number and they subse-
quently decreased. The intra-articular injection of IL-1 led to the
same kinetics as in the present study [25], suggesting that the
leukocyte infiltrating activity of IL-1 was mediated by IL-8 pro-
duction in synovial cells as demonstrated in vitro [7, 8]. However,
a definite statement about the involvement of IL-1 in DRA cannot
be made from our clinical data. We demonstrated in vivo that
indomethacin inhibited the IL-8-induced infiltration of leuko-
cytes. Indomethacin was also reported to inhibit adhesivity and
chemotaxis of neutrophils in response to zymosan-activated serum
or N-formyl-methionyl-leucyl-phenylalanine (FMLP) [26] and the
release of lysosomal enzymes and the production of superoxide
anions by neutrophils [27].
The IL-8-induced accumulation of inflammatory cells is associ-
ated with joint redness, which is not accompanied by significant
joint swelling. Rampart et al [28] noted that the administration of
IL-8 and vasodilator substances such as PGE2 into the skin
synergistically induced both neutrophil accumulation and plasma
extravasation. It is thus evident that IL-8 alone directly induces
leukocyte infiltration, but does not form edema. Thus, indometh-
acin may also inhibit edema formation by suppressing PGE2
synthesis.
Tumor necrosis factor-a stimulated IL-8 production in cultured
synovial cells. Interleukin-8 production is mainly controlled at the
activation step of the transcription factor, NF-kB [29, 30]. NF-kB
may be activated in synovial cells and endothelial cells in joints of
patients with RA (particularly those with active disease), and it
regulates the expression of many genes involved in immune and
inflammatory proteins such as cytokines, enzymes and adhesion
molecules [31, 32]. The proinflammatory cytokines IL-1b and
TNF-a activate NF-kB, and their transcriptions are also activated
by NF-kB. Thus, products of the genes that are regulated by
NF-kB cause the activation of NF-kB [32]. This type of positive
regulatory loop may amplify and perpetuate local inflammatory
responses. In fact, it has been reported that NF-kB is activated in
the synovial tissues of patients with RA [33]. Since IL-8 is
Fig. 2. Time course of leukocyte infiltration in joint fluids induced by
intra-articular injection of IL-8. Symbols are: ( ) IL-8; (– –) IL-8 1
IM-F; (– z –) saline controls. Leukocyte infiltration occurred with maximal
accumulation 4 hours after injection of IL-8 (0.5 mg). The oral adminis-
tration of indometacin farnesil (IM-F) reduced leukocyte infiltration into
the joint space in the IL-8-induced synovitis. Data are expressed as
mean 6 SE (N 5 8 for IL-8, N 5 8 for IL-8 1 IM-F and N 5 4 for saline).
*P , 0.05 and **P , 0.01 vs. IL-8.
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Fig. 3. Light microscopy of the synovial tissues
obtained 4 hours after injection of interleukin
(IL)-8 with or without oral administration of
indometacin farnesil (hematoxylin and eosin
stain, 3200). (A) Synovial tissue after intra-
articular injection of IL-8, showing infiltration
of a large number of neutrophils on the
superficial layers of the synovium. (B) Synovial
tissue after intra-articular injection of IL-8 with
oral administration of indometacin farnesil,
showing that neutrophil infiltration was
reduced. (C) Synovial tissue after intra-articular
injection of endotoxin-free saline, showing
normal appearance.
abundant in synovial fluids of patients with DRA, NF-kB may also
be activated in the affected synovial tissue of DRA.
We demonstrated that dexamethasone suppressed TNF-a-
induced IL-8 synthesis in cultured synovial cells. Activation of
NF-kB, for example by cytokines, is blocked by glucocorticoids
[32, 34]. Glucocorticoid-receptor complexes bind the p65 subunit
of NF-kB and this prevents NF-kB activation of inflammatory
genes. Synthesis of IkBa is stimulated by the binding of glucocor-
ticoid-receptor complexes to a glucocorticoid response element in
the promoter region of the IkBa gene.
In conclusion, IL-8 levels were markedly elevated in the joint
fluids of patients with DRA. Interleukin-8 released from synovial
cells may be an important factor to induce acute inflammation in
DRA. Dexamethasone and indomethacin may be effective for the
arthritis through inhibition of production and chemotactic action
of IL-8, respectively.
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APPENDIX
Abbreviations used in this article are: AET, 2-aminoethylisothiouro-
nium bromide; AGE, advanced glycation end products; b2m, beta-2-
microglobulin; BSA, bovine serum albumin; DMEM, Dulbecco’s modified
Eagle’s medium; DRA, dialysis:-related arthritis; GAPDH, glyceralde-
hyde-3-phosphate-dehydrogenase; HBSS, Hank’s balanced salt solution;
HD, hemodialysis; IL, interleukin; LPS, lipopolysaccharide; OA, osteoar-
thritis; PCR, polymerase chain reaction; RA, rheumatoid arthritis; SDS,
sodium dodecyl sulfate; SRBC, sheep erythrocytes; TNF-a, tumor necrosis
factor alpha.
Fig. 4. Effect of dexamethasone (DEX) on
tumor necrosis factor alpha (TNF-a)-
stimulated expression of interleukin (IL)-8
mRNA. Human synovial cells were incubated
with dexamethasone for 1 hour, followed by the
addition of TNF-a (0.5 ng/ml) and further
incubation for 6 hours. (A) Autoradiograph of a
Northern blot. (B) Densitometric analysis of the
autoradiographs from two separate
experiments. The amount of IL-8 mRNA was
corrected with that of GAPDH mRNA
(ANOVA P , 0.01). *P , 0.05 and **P , 0.01
vs. TNF-a (0.5 ng/nl) and DEX (0 M).
Fig. 5. Effect of dexamethasone (DEX) on tumor necrosis factor-alpha
(TNF-a)-stimulated production of interleukin (IL)-8. Human synovial
cells were incubated with 1027 M dexamethasone for 1 hour, followed by
addition of TNF-a (0.5 ng/ml) and further incubation for 24 hours. *P ,
0.05 vs. TNF, by ANOVA.
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